Book a demo
Skip to content

Stonewake Monitoring

Halozyme Therapeutics files 8-K covering a new debt obligation

Halozyme Therapeutics, Inc. submitted a Form 8-K to the SEC on 2026-09-22 that reports a debt obligation among other items.

Export financeUSAPublished · 3 sourced facts

Halozyme Therapeutics, Inc., a Delaware-incorporated biological products company listed on Nasdaq under the ticker HALO, filed a Form 8-K with the SEC dated 2026-09-22.[1][2]

The filing carries items 1.01, 2.03, 3.02, and 9.01, with the debt obligation event recorded under the same 2026-09-22 period.[1]

The submission is identified by accession number 0001193125-26-398015, and the matched document is d148460d8k.htm.[1]

The company's CIK is 0001159036.[1][2]

Separately, an executive departure at the company was recorded on 2026-08-18.[3]

Sources

  1. [1]SEC EDGAR: 8-K, 0001193125-26-398015, 22 Sep 2026
  2. [2]SEC EDGAR: CIK 0001159036, HALOZYME THERAPEUTICS, INC.
  3. [3]SEC EDGAR

SEC EDGAR

← All briefs